case based panel discussion - stage 3 nsclc treatment standard and the risk of potential pneumonitis
Published 4 years ago • 129 plays • Length 4:34Download video MP4
Download video MP3
Similar videos
-
11:27
case based panel discussion - stage 3 nsclc, frail patient competing risks, best treatment approach?
-
10:08
case based panel discussion stage 3 nsclc - does timing of treatment make a difference in response.
-
3:48
treating stage iii nsclc - case based panel discussion
-
5:17
immunotherapy in stage iii nsclc - case based panel discussion
-
6:17
case based panel discussion - stage 3 nsclc - patients with pdl1 - 0, is immunotherapy beneficial?
-
11:25
case based panel discussion - stage3 nsclc should we do molecular tests? effect treatment decision?
-
9:04
case based panel discussion - stage3 nsclc - checkmate 227 immuno combo, another treatment option?
-
6:30
stage 3 squamous lung cancer with low pd-l1 - case based panel discussion
-
8:16
case based panel discussion - stage 3 nsclc best schedule - durvalumab/imfinzi in varying patients
-
13:00
stage 3a node-positive lung adenocarcinoma with alk rearrangement - case based panel discussions
-
5:39
non-bulky nsclc 2b disease: the role of chemoimmunotherapy - case based panel discussion
-
6:15
treatment options for egfr nsclc - case based panel discussion
-
6:29
case based panel discussion nsclc – does a positive her2 mutation effect treatment decisions?
-
7:12
egfr mutated adenocarcinoma - case based panel discussions
-
4:10
how oncologists stage disease - case based panel discussion
-
6:00
case based panel discussions - egfr mutation & met - treatment decisions, level of met amplification
-
5:06
case based panel discussion - egfr mutation and high pdl1 - what is the role of immunotherapy in tre
-
8:20
case based panel discussion - egfr - progression, next steps - a place for chemo & immunotherapy? v2
-
5:32
unresctable nsclc - concurrent chemo & radiation, followed by immunotherapy, potential pneumonitis